New drug combo tested for Tough-to-Treat lung cancer
NCT ID NCT05215951
Summary
This study aimed to test the effectiveness and safety of a combination treatment for adults with advanced non-small cell lung cancer (NSCLC) who have specific, less common genetic mutations. The treatment combined a targeted pill (osimertinib) with standard chemotherapy drugs given by IV. The goal was to see if this combination could better control the cancer's growth. The trial was terminated early after enrolling only 4 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Chengdu, 610041, China
-
Research Site
Harbin, 150049, China
-
Research Site
Mianyang, 621000, China
-
Research Site
Nanchong, 637000, China
-
Research Site
Yibin, 644000, China
-
Research Site
Zhengzhou, 450000, China
Conditions
Explore the condition pages connected to this study.